BACTOCILL
Pronunciation: ox-a-SIL-in

What it isPenicillinase-resistant penicillin; methicillin-susceptible staphylococcal infection.
Why this oneIt is nafcillin's close efficacy peer; selection usually turns on formulary and tolerability rather than antibacterial reach.
What limits itHepatotoxicity and interstitial nephritis stand out. It does not cover MRSA and requires frequent administration.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Staphylococcal infection, mild-moderate | Adults | 250-500 mg IV q4-6h | 250-500 mg IV q4-6h | |
| Severe infection | Adults | 1 g IV q4-6h | 1 g IV q4-6h |
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy Animal studies show no fetal harm; no adequate well-controlled human studies
Lactation Undefined
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 1 g | inj | per unit | not offered | |
| 2 g | inj | per unit | not offered |
Generic entryPre-1982
NO BOXED WARNINGS
Principal riskHepatotoxicity; interstitial nephritis
Legacy pregnancy categoryB
Defining liabilityAllergy, gastrointestinal effects and agent-specific renal, hepatic, hematologic or interaction risks.